P. Abraham

Genome characterization of monkeypox cases detected in India: Identification of three sub clusters among A.2 lineage

The paper analyzes Monkeypox virus genomes from India, identifying three subclusters within the A.2 lineage and additional APOBEC3 mutations.

Protective efficacy of COVAXIN(R) against Delta and Omicron variants in hamster model

This study evaluates COVAXIN's protective efficacy against Delta and Omicron variants in hamsters, showing improved protection with a third dose and reduced disease severity.

Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concerns

This study compares IgG and neutralizing antibody responses in vaccinated and unvaccinated individuals infected with the Omicron variant of SARS-CoV-2, showing reduced neutralization against Omicron compared to earlier variants.

An in vitro and in vivo approach for the isolation of Omicron variant from human clinical specimens

The paper isolates the Omicron variant from Syrian hamsters and compares its genetic changes to human clinical specimens and Vero CCL-81 cell passages.

ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection

The paper develops a monoclonal antibody cocktail (ZRC-3308) effective against multiple SARS-CoV-2 variants in Syrian hamsters.

Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individuals

This study evaluates immune response in Covishield vaccinated and recovered individuals against the Delta variant, finding higher protection in breakthrough cases and recovered individuals compared to single or double vaccinated groups.

Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152

This study assesses the neutralization efficacy of sera from COVID-19 recovered cases and BBV152 vaccinees against SARS-CoV-2 variants B.1.351 and B.1.617.2, showing reduced titers but still protective responses.

Isolation of SARS-CoV-2 B.1.1.28.2 P2 variant and pathogenicity comparison with D614G variant in hamster model

The paper isolates the SARS-CoV-2 B.1.1.28.2 (P.2) variant from travelers and compares its pathogenicity to the D614G variant in hamsters, finding it more severe and with reduced neutralization.

Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1

This study compares neutralizing antibody responses in Covishield-vaccinated individuals and COVID-19 recovered subjects against B.1 and B.1.617.1 variants, finding higher neutralization in recovered subjects.

SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant

This study compares the pathogenicity of SARS-CoV-2 variants B.1 and B.1.617.1 in hamsters, finding B.1.617.1 causes greater body weight loss, higher viral load, and more severe lung lesions.

Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine

This study evaluates the neutralizing efficacy of B.1.1.28.2 variant against sera from natural infection and BBV152 vaccine recipients, showing reduced neutralization compared to D614G.

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

The paper assesses the neutralizing ability of sera from BBV152 vaccinees and convalescent COVID-19 patients against B.1.617 variants.

Comparison of the pathogenicity and virus shedding of SARS CoV-2 VOC 202012/01 and D614G variant in hamster model

This study compares the pathogenicity and virus shedding of SARS-CoV-2 VOC 202012/01 and D614G variants in hamsters, finding higher viral shedding and mild lung pathology with VOC 202012/01.

Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection

This study evaluates two doses of ZyCoV-D DNA vaccine in rhesus macaques, finding that the 2mg dose via Needle Free Injection System provides better immune response and protection against SARS-CoV-2.

Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152

This study evaluates the safety and immunogenicity of a SARS-CoV-2 vaccine BBV152 in mice, rats, and rabbits, showing high antibody titers and Th1-biased responses with the TLR7/8 agonist adjuvant.